April 2020 FDA Recall Memantine Hydrochloride by The Harvard Drug Group
D-1262-2020 - Failed dissolution specifications

This Class III drug recall was voluntarily initiated by The Harvard Drug Group on April 24, 2020 for the product Memantine Hydrochloride. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed in AL, FL, IA, NY, OH, TX and the recall is currently terminated.

Recall Number: D-1262-2020

Reason for Recall
Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.
Initiated
04-24-2020
Reported
05-20-2020
Quantity
678 cartons

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
The Harvard Drug Group
AL, FL, IA, NY, OH, TX
Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, India; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 47152 USA. NDC: 0904-6735-61

Batch or Lot Expiration Information

Lot# : M02199D, M02246D, Exp 5/2020